Safety and Efficacy of Nerandomilast in Patients With Pulmonary Fibrosis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

ABSTRACT Objective Nerandomilast, an oral phosphodiesterase‐4 (PDE4) inhibitor, has shown potential in slowing the progression of pulmonary fibrosis. This meta‐analysis evaluated the efficacy and safety of nerandomilast in preserving lung function among patients with pulmonary fibrosis. Methods MEDL...

Descripció completa

Dades bibliogràfiques

Autors principals:	Humna Shahzad, Usama Afzaal, Fahad Saleem, Ahmad Hassan Gul, Freya Thummar, Hafiz Nadir Murtaza, Abel Gelan, Maria Ahsan, Rafay Irfan, Ahmad Nawaz, Uzair Jafar, Asma'a Munasar Ali Alsubari, Muhammad Ehsan, Ahmed Nadeem, Praveen Kumar Komminni, Juan Iribarren
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-03-01
Col·lecció:	The Clinical Respiratory Journal
Matèries:	IPF meta‐analysis nerandomilast PDE4 inhibitors pulmonary fibrosis
Accés en línia:	https://doi.org/10.1111/crj.70181
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!